ReviewAmerican journal of physiology. Lung cellular and molecular physiology2021
Healing after COVID-19: are survivors at risk for pulmonary fibrosis?
Review in American journal of physiology. Lung cellular and molecular physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 234 citations in OpenAlex.
- Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial.The European respiratory journal · 2025Trial
- Methylprednisolone in the management of post-COVID-19 interstitial lung disease: A randomized trial (STERCOV-ILD).Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Extracellular-to-total body water ratio is associated with comorbidity and cardiorespiratory fitness in older adults with post-COVID-19 syndrome.Frontiers in nutrition · 2026Article
- Pulmonary sequelae of SARS-CoV-2 infection: a narrative review of long-term functional, radiological, and clinical outcomes in COVID-19 survivors, with a regional focus on Saudi Arabia.Frontiers in physiology · 2026Review
- Bioresponsive gelatin-coated silk fibroin nanoparticles enhance roxadustat therapy in experimental pulmonary fibrosis.Frontiers in pharmacology · 2026Article
- COVID-19 and Interstitial Lung Disease.Medicina (Kaunas, Lithuania) · 2025Review
- Review
- Breathe Better After COVID: The Impact of a Two-Week Pulmonary Rehabilitation Program on Pulmonary Function, Inflammatory Markers, and Quality of Life in Post-COVID Syndrome.Journal of clinical medicine · 2025Article
- Determination of both the expression and serum levels of epidermal growth factor and transforming growth factor β1 genes in COVID-19.Scientific reports · 2025Article
- Early pulmonary fibrosis-like changes between delta and pre-delta periods in patients with severe COVID-19 pneumonia on mechanical ventilation.Scientific reports · 2024Article
- Pulmonary Function, Functional Capacity, Respiratory, and Locomotor Muscle Strength after Severe to Critically Ill COVID-19: A Long-Term Study.Tuberculosis and respiratory diseases · 2024Article
- Metabolomic characterization of COVID-19 survivors in Jilin province.Respiratory research · 2024Article
- Post-COVID Interstitial Lung Disease: How do We Deal with This New Entity?Balkan medical journal · 2024Article
- Beneficial Effects on Exercise Capacity Associated with a Combination of Lactoferrin, Lysozyme, Lactobacillus, Resveratrol, Vitamins, and Oligoelements in Patients with Post-COVID-19 Syndrome: A Single-Center Retrospective Study.Journal of clinical medicine · 2024Article
- Association of clinical and imaging characteristics with pulmonary function testing in patients with Long-COVID.Heliyon · 2024Article
- Article
- Pulmonary redox imbalance drives early fibroproliferative response in moderate/severe coronavirus disease-19 acute respiratory distress syndrome and impacts long-term lung abnormalities.Annals of intensive care · 2024Article
- Drugs targeting CTGF in the treatment of pulmonary fibrosis.Journal of cellular and molecular medicine · 2024Review
- Anti-synthase syndrome associated with SARS-Cov-2 infection.BMC pulmonary medicine · 2024Article
- Research progress of post-acute sequelae after SARS-CoV-2 infection.Cell death & disease · 2024Review
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The novel SARS-CoV-2 coronavirus, which is responsible for COVID-19 disease, was first reported in Wuhan, China, in December of 2019. The virus rapidly spread, and the World Health Organization declared a pandemic by March 2020. With millions of confirmed cases worldwide, there is growing concern and considerable debate regarding the potential for coronavirus infection to contribute to an appreciable burden of chronic respiratory symptoms or fibrotic disease among recovered individuals. Because the first case of COVID-19 was documented less than one year ago, data regarding long-term clinical outcomes are not yet available, and predictions for long-term outcome are speculative at best. However, due to the staggering number of cases and the severity of disease in many individuals, there is a critical need to consider the potential long-term implications of COVID-19. This review examines current basic and clinical data regarding fibrogenic mechanisms of viral injury in the context of SARS-CoV-2. Several intersecting mechanisms between coronavirus infection and fibrotic pathways are discussed to highlight factors and processes that may be targetable to improve patient outcome. Reports of post-infection sequelae from previous coronavirus outbreaks are presented toward the goal of improved recognition of potential contributing risk factors for fibrotic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.